The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
 
Tomás Pascual
Consulting or Advisory Role - Novartis; Roche/Genentech
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Veracyte
 
Daniel G. Stover
Consulting or Advisory Role - Novartis
Research Funding - NeoGenomics Laboratories (Inst)
 
Astrid Thuerigen
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Rodrigo Sanchez-Bayona
Honoraria - AstraZeneca; GlaxoSmithKline; Lilly; Novartis; Seagen
Consulting or Advisory Role - GlaxoSmithKline; Lilly; Novartis
Speakers' Bureau - AstraZeneca; Novartis
Expert Testimony - AstraZeneca; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Charles M. Perou
Leadership - GeneCentric
Stock and Other Ownership Interests - Bioclassifier; GeneCentric; Reveal Genomics
Consulting or Advisory Role - Bioclassifier; GeneCentric; NanoString Technologies; Reveal Genomics; Veracyte
Patents, Royalties, Other Intellectual Property - royalties from PAM50 breast cancer gene patent application, and from lung gene signature patent
 
Eva M Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Ana Casas
No Relationships to Disclose
 
Patricia Spears
Consulting or Advisory Role - Pfizer
 
Estelle Roux
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Fei Su
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Huilin Hu
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; EuroPharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Ann H. Partridge
Patents, Royalties, Other Intellectual Property - I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate
 
Guillermo Villacampa
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Speakers' Bureau - MSD Oncology; Pierre Fabre
 
Juan Manuel Ferrero-Cafiero
No Relationships to Disclose
 
Lisa A. Carey
Research Funding - AstraZeneca (Inst); NanoString Technologies (Inst); Seagen (Inst); Veracyte (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly; Novartis (Inst); SeaGen
 
Aleix Prat
Employment - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc